Kezar gains on FDA nod to test autoimmune hepatitis drug in humans

Kezar Life Sciences

03/10/2022 21:41

** Shares of drug developer Kezar Life Sciences  KZR.O  jump
~11% to $9.80 in extended trading 
    ** KZR says FDA cleared investigational new drug application
for its drug zetomipzomib  urn:newsml:reuters.com:*:nBw3cBH5Sa  
    ** Co plans to test zetomipzomib as a potential treatment of
autoimmune hepatitis (AIH), in which the immune system attacks
the liver and causes inflammation and tissue damage
    ** Adds that its PORTOLA trial will evaluate safety and
efficacy of zetomipzomib in AIH patients who are insufficiently
responding to standard of care or have relapsed
    ** As of last close, stock down 47.4% YTD 
 (Reporting by Bhanvi Satija in Bengaluru)
 ((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91
9873062788;))